Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Newly Diagnosed High-risk B-all; Risk-adapted Post-induction Therapy For High-risk B-all, Mixed Phenotype Acute Leukemia, And Disseminated B-lly
• Age: Between 1 years - 25 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  In order to participate in this study, the following criteria must be met: White blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy): 1) Age 1-9.99 years: WBC >= 50,000/uL 2) Age 10-24.99 years: Any WBC White blood cell count (WBC) criteria for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy): 1) Age 1-24.99 years: any WBC.
  

You may not be eligible for this study if the following are true:

• You will not be able to participate in this study if: 1) Patients with Down syndrome are not eligible (patients with Down syndrome and B-ALL are eligible for AALL1731, regardless of NCI risk group). 2) Patients with acute undifferentiated leukemia (AUL) 3) With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for the current diagnosis of B-ALL, MPAL, or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL1732.